Regeneron stock trades steady as Eylea and Dupixent growth support earnings

Regeneron stock remains supported by growing Eylea and Dupixent revenue, with recent quarterly earnings and a solid pipeline shaping the outlook for investors.

Regeneron stock, tied to Regeneron Pharmaceuticals Inc. (ISIN US75886F1075) and listed on Nasdaq, continues to draw investor attention as the biotech group leans on rising Eylea and Dupixent sales to support earnings and cash flow in recent quarters. In its latest reported quarter for fiscal 2025 according to company filings, Regeneron generated total revenue in the mid single digit billion dollar range, driven by double digit growth from key ophthalmology and immunology franchises. While exact recent market prices vary by day and venue, the stock has generally traded within a robust range over the past twelve months, reflecting both the fundamental strength of its commercial portfolio and the market’s sensitivity to drug lifecycle and competition.

Revenue grows year over year

According to Regeneron’s most recent annual report for fiscal 2024, the company recorded total revenue of around $13 billion, representing an increase versus the prior year as both product sales and collaboration revenue grew. The comparison with fiscal 2023, when revenue was closer to $12 billion, underscores a year over year expansion of roughly $1 billion, driven largely by higher demand for the eye drug Eylea and the asthma and eczema therapy Dupixent. The earnings release for that period highlights that Dupixent, which Regeneron co-develops and co-commercializes with a major European pharmaceutical partner, contributed several billion dollars in net sales recognized by Regeneron, with growth in the double digit percentage range compared with the previous year.

In the company’s latest quarterly report for Q1 2025, Regeneron pointed to continued momentum in its core franchises, reporting total quarterly revenue in the multiple billion dollar range and noting that product revenue expanded versus Q1 2024. The company’s management explained in the filing that higher Eylea sales in ophthalmology and expanding Dupixent use across indications helped offset declines in COVID-19 related antibody revenue that had previously supported results. The quantified comparison in this quarterly data shows that while COVID-19 revenues decreased year over year, underlying non-COVID franchises grew enough to deliver overall revenue growth and maintain profitability.

Eylea drives multi billion dollar sales

Eylea, Regeneron’s anti-VEGF therapy for eye conditions such as age-related macular degeneration, remains one of the company’s largest revenue contributors. In fiscal 2024, the company reported Eylea net product sales in the United States of several billion dollars, slightly below the peak reached in earlier years but still providing a substantial cash flow base. The year over year trend has shown modest decline in certain periods due to competitive pressure and lifecycle effects, yet the absolute level of sales continues to be significant. In parallel, Regeneron has been working on life-cycle management strategies for Eylea, including higher-dose formulations and extended dosing intervals, to sustain its role in the company’s portfolio.

Dupixent stands out as a growth engine. In the 2024 annual report, Regeneron disclosed that its share of Dupixent-related revenue reached multiple billion dollars, rising strongly compared with the prior year as new indications in chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyposis, and pediatric atopic dermatitis expanded the addressable patient population. The quantified comparison shows that Dupixent revenue increased by more than a billion dollars year over year, making it one of the most important drivers of Regeneron’s top line growth. For investors, this trajectory matters because it underpins both current earnings and the potential for further expansion as additional indications are approved and penetration deepens.

Margin profile and cash generation

Beyond revenue, Regeneron’s profitability metrics in recent filings have remained solid. The company has reported operating income in the several billion dollar range in fiscal 2024, with operating margins that are strong by biotech standards. Net income has also remained in the multi billion dollar area, reflecting efficient cost management and the high gross margins typical of biologic drugs. Cash flow from operations in the most recent fiscal year was substantial, helping to support ongoing research and development investment across multiple therapeutic areas.

In quarterly reports through Q1 2025, Regeneron continued to highlight robust R&D spending, often reaching into the billions of dollars annually, as it advances a broad pipeline including oncology, ophthalmology, immunology, and rare diseases. The balance between strong cash generation and high reinvestment rates is central to the company’s long term story. While near term earnings are supported by Eylea and Dupixent, the future value of Regeneron stock will depend on how effectively this R&D spending translates into new approved therapies and label expansions.

Pipeline and regulatory milestones

Regeneron has reported a series of pipeline milestones in recent investor presentations, including late stage trials for oncology antibodies and gene therapy initiatives. For example, the company has mentioned phase 3 results for certain oncology assets targeting PD-1 and other immune checkpoints, with data sets that could support regulatory filings in key markets. Additionally, Regeneron is investing in genetic medicine platforms that aim to address rare inherited diseases, building on its expertise in monoclonal antibodies and biologics.

Regulatory news over the past year has included approvals or label expansions for Dupixent in new indications, each contributing to the drug’s growth trajectory. These milestones are reflected in the quantified revenue comparisons in the financial reports, where new indications help drive year over year increases. For investors following Regeneron stock, such pipeline and regulatory developments provide context for the company’s valuation, as successful trials and approvals can expand future revenue while setbacks can pressure the share price.

Valuation context and trading range

Regeneron’s market capitalization has recently been in the tens of billions of dollars, placing it among the larger constituents of major US equity indices. The stock is a member of the S&P 500, and its inclusion in this benchmark means that many index funds and ETFs hold it as part of their portfolios. Over the past twelve months, Regeneron shares have generally traded within a range that reflects both the strength of its existing franchises and market concerns about patent expiry, competition, and pricing pressures in the pharmaceutical sector.

From a technical perspective, chart data from common market portals show that Regeneron stock has tested various support and resistance levels during this period, with investor reactions often tied to earnings releases, clinical trial updates, and broader risk sentiment in healthcare equities. While day to day volatility can be significant, the longer term trend has been influenced by the steady expansion of Dupixent revenue and the resilience of Eylea sales.

Dupixent strengthens immunology franchise

Dupixent is a key representative product within Regeneron’s immunology portfolio. Co-developed with a major European pharmaceutical partner and indicated for conditions such as atopic dermatitis and asthma, it has become a multi billion dollar product globally. Regeneron’s share of this revenue, as reported in its annual filings, has risen year over year, supporting both top line growth and margin resilience. The drug’s expanding label, covering additional patient groups and comorbid conditions, provides a pathway for further growth.

For Regeneron, Dupixent’s success also highlights the value of its antibody discovery platform and collaboration model. By leveraging partnerships and focusing on biologics, the company has built a diversified set of revenue streams that include both wholly owned products and co-commercialized therapies. The performance of Dupixent therefore serves as both a financial anchor and a proof point for Regeneron’s broader strategy.

Regeneron stock in the market

Regeneron stock trades on Nasdaq under the ticker REGN, providing liquidity and visibility among US and international investors. The shares are widely held by institutional investors, including mutual funds and ETFs that track the S&P 500 and sector-specific healthcare indices. While recent precise prices and intraday moves depend on the trading session, the stock’s valuation in the tens of billions of dollars and its status as a major biotech name are clear anchors.

For investors, the current positioning of Regeneron stock reflects a balance between strong existing franchises, a meaningful pipeline, and the typical risks of drug development and regulatory scrutiny. Earnings and revenue metrics for fiscal 2024 and Q1 2025 show multi billion dollar revenue, growing Dupixent sales, and resilient Eylea income, alongside significant R&D investment aimed at sustaining growth beyond the current flagship products.

Regeneron stock key data

• Company: Regeneron Pharmaceuticals Inc.
• ISIN: US75886F1075
• Ticker: NASDAQ: REGN
• Trading venue: Nasdaq
• Sector / Industry: Health Care / Biotechnology
• Index membership: S&P 500